MOCRAVIMOD DOES NOT HAVE A CLINICALLY RELEVANT DRUG-DRUG INTERACTION WITH STRONG CYP3A4 INHIBITOR ITRACONAZOLE

被引：0
|
作者：
Huntjens, Dymphy [1 ]
Oehen, Stephan [1 ]
Kueenburg, Elisabeth [1 ]
机构：
[1] Priothera SAS, St Louis, France
来源：
BONE MARROW TRANSPLANTATION | 2024年 / 59卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P768
引用
收藏
页码：740 / 741
页数：2
相关论文
共 50 条
  • [31] Mechanism of clinically relevant drug-drug interaction between cerivastatin and gemfibrozil
    Shitara, Y
    Hirano, M
    Sato, H
    Sugiyama, Y
    DRUG METABOLISM REVIEWS, 2004, 36 : 297 - 297
  • [32] Clinical Assessment of Mocravimod As a Victim of Drug-Drug Interactions Via CYP3A Metabolism and Transporters
    Huntjens, Dymphy
    Oehen, Stephan
    Kueenburg, Elisabeth
    BLOOD, 2024, 144 : 5774 - 5775
  • [33] Application of CYP3A4 in vitro data to predict clinical drug-drug interactions;: predictions of compounds as objects of interaction
    Youdim, Kuresh A.
    Zayed, Aref
    Dickins, Maurice
    Phipps, Alex
    Griffiths, Michelle
    Darekar, Amanda
    Hyland, Ruth
    Fahmi, Odette
    Hurst, Susan
    Plowchalk, David R.
    Cook, Jack
    Guo, Feng
    Obach, R. Scott
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (05) : 680 - 692
  • [34] Drug-Drug Interaction between (S)-Rivaroxaban and Orthopedics Treatment Drugs Mainly Undergoing CYP3A4 Metabolism
    Shi, Jian-Sheng
    Guo, Yang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (03): : 613 - 615
  • [35] Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates
    Umehara, Ken-ichi
    Huth, Felix
    Won, Christina S.
    Heimbach, Tycho
    He, Handan
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (03) : 152 - 163
  • [36] APPLICATION OF CYP3A4 IN VITRO DATA TO PREDICT CLINICAL DRUG-DRUG INTERACTIONS; PREDICTIONS OF COMPOUNDS AS OBJECTS OF INTERACTION
    Youdim, Kuresh A.
    Dickins, Maurice
    Phipps, Alex
    Darekar, Amanda
    Hyland, Ruth
    Fahmi, Odette
    Hurst, Susan
    Cook, Jack
    Plowchalk, David
    Guo, Feng
    Obach, Scott
    DRUG METABOLISM REVIEWS, 2008, 40 : 84 - 85
  • [37] A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects
    Juif, Pierre-Eric
    Boehler, Margaux
    Donazzolo, Yves
    Bruderer, Shirin
    Dingemanse, Jasper
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (09) : 1121 - 1128
  • [38] Biotransformation of Ilaprazole in Human Liver Microsomes and Human: Role of CYP3A4 in Ilaprazole Clearance and Drug-Drug Interaction
    Pu, Jie
    Wang, Fen
    Tang, Wei
    Zhu, Mingshe
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (10) : 1453 - 1461
  • [39] Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin
    Dutreix, Catherine
    Lorenzo, Sebastien
    Wang, Yanfeng
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (08) : 915 - 920
  • [40] Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone
    Lee, Lucy
    Thoolen, Martin
    Ma, Jiyuan
    Kaushik, Diksha
    Golden, Lee
    Kong, Ronald
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (12): : 1283 - 1290
12345